Intervention of s100a16 can promote the progression and angiogenesis of renal cell carcinoma through the VEGF/VEGFR2 signal transduction pathway and lead to poor prognosis of renal cell carcinoma. These findings suggest a potential target for the development of anticancer strategies for ...
MT1G induces lipid droplet accumulation through modulation of H3K14 trimethylation accelerating clear cell renal cell carcinoma progression Introduction Renal cell carcinoma (RCC) tumors, which arise from renal tubular epithelial cells, are among the most commonly developed urological malignancies, as they ...
Hypoxia-triggered ERRα acetylation enhanced its oncogenic role and promoted progression of renal cell carcinoma by coordinating autophagosome-lysosome fusion Chun Feng Demin Kong Zhaowei Xu ResearchOpen Access16 Jan 2025Cell Death & Disease Volume: 16, P: 23 ...
Cancer-associated fibroblasts promote renal cell carcinoma progression 来自 Semantic Scholar 喜欢 0 阅读量: 83 作者:Y Xu,Y Lu,J Song,B Dong,W Kong,W Xue,J Zhang,Y Huang 摘要: The aim of this study was to determine the ef...
Treatment for renal cell carcinoma (RCC) has improved dramatically over the last decade, shifting from high-dose cytokine therapy in combination with surgical resection of tumors to targeted therapy, immunotherapy, and combination therapies. However, cur
[1],包括2021年最新公布的KEYNOTE581研究在内的多项以免疫检查点抑制剂为基础的联合治疗III期临床试验在转移性透明细胞肾细胞癌一线治疗中显示出优越的临床疗效,最终奠定了目前免疫联合治疗在晚期肾癌患者中新一线治疗地位[2-4],但多项关于透明细胞肾细胞癌(clear cell renal cell carcinoma, CCRCC)的组学研究则...
Treatment for renal cell carcinoma (RCC) has improved dramatically over the last decade, shifting from high-dose cytokine therapy in combination with surgical resection of tumors to targeted therapy, immunotherapy, and combination therapies. However, cur
Kidney Renal Clear Cell Carcinoma (KIRC) accounts for 75% of all renal cancers. Previous study had conflict evidences regarding NR1B2 role in cancer, and its expression and biological role in KIRC remained unclear. Our aims were to characterize the role
Clear cell renal cell carcinoma (ccRCC) is a complex disease with remarkable immune and metabolic heterogeneity. Here we perform genomic, transcriptomic, proteomic, metabolomic and spatial transcriptomic and metabolomic analyses on 100 patients with ccRC
Insights into the role of the tumor suppressor pVHL in oxygen sensing motivated the testing of drugs that target the transcription factor HIF or HIF-responsive growth factors, such as VEGF, for the treatment of cancers caused by VHL inactivation, such as clear-cell renal cell carcinoma (ccRCC)...